The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|April 30, 2020
INTERPHEX Rescheduled for 2021 Due to COVID-19
Author(s)Pharmaceutical Technology Editors
The event will be rescheduled for April 20–22, 2021 at the Javits Center in New York City.
Advertisement
Reed Exhibitions announced on April 30, 2020 that it was rescheduling its pharmaceutical industry event, INTERPHEX - previously postponed to July 15–17 at the Javits Center in New York City - to April 20–22, 2021 at the same venue due to the continuing spread of COVID-19.
“Our entire team is here to support all of our customers and partners and we are passionate about providing new options for us to come together, virtually throughout the summer and with smaller face-to-face interactions opportunities in the fall, when we can. Stay tuned for more information coming soon,” said Kate Scott, event director, INTERPHEX, in a press release.
The announcement comes days after INTERPHEX announced the launch of RECONNEX 365, an online resource that provides exhibitor expertise and technical know-how year-round.
“You will see even more tools, resources, and innovative solutions coming from the INTERPHEX team,” added Scott in the press release. “These will allow you to make new connections; meet leading suppliers; source technologies, products, and services; and learn from industry subject matter experts to enable you to find solutions to develop and manufacture cost-effective, quality therapeutics for the global population.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement